MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease
By L. Kordelas, V. Rebmann, Anna‐Kristin Ludwig, S. Radtke, Johannes Ruesing, T. Doeppner, Matthias Epple, P. Horn, D. Beelen, B. Giebel. Leukemia, 2014
961 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/aff01cb5f11511a94b7470a6895b657f11c5f360
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- C. Théry
- Raghu Kalluri
- Suresh Mathivanan
- Richard J. Simpson
- X. Breakefield
- A. Llorente
- Valerie S. LeBleu
- W. Stoorvogel
In Molecular Biology
- C. Théry
- Suresh Mathivanan
- Richard J. Simpson
- Raghu Kalluri
- X. Breakefield
- A. Llorente
- Valerie S. LeBleu
- David W. Greening
Citations in the corpus
- Advances in therapeutic applications of extracellular vesicles (2019, methodology): “The therapy was associated with improvement in clinical GvHD symptoms within the first week of MSC-EV therapy that remained stable 4 months after treatment (66).”
- The biology, function, and biomedical applications of exosomes (2020, positive): “MSCderived exosomes have been proposed to be therapeutic by themselves (222), and the use of MSC-derived exosomes in the treatment of a patient with graft versus host disease showed that repeated injections were well tolerated, were not associatedwith substantial side effects, and resulted in patien”
- EVpedia: a community web portal for extracellular vesicles research (2015, background): “…approaches have been pursued to utilize EVs and their mimetics for vaccine, che- motherapeutic drug and siRNA delivery (Alvarez-Erviti et al., 2011; Chaput et al., 2005; Jang et al., 2013; Kordelas et al., 2014; Lai et al., 2010; Lee et al., 2012; Simpson et al., 2009; Sun et al., 2010).”
- Manufacturing Exosomes: A Promising Therapeutic Platform. (2018, neutral): “Specifically, both human and mouse neuroblastoma lines showed that switching from FBS-containing to serum-free medium left the resultant exosomes from both species unchanged in terms of biophysical and size characteristics [35].”
- Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, methodology): “Furthermore, donor-to-donor variabilities have to be considered as comparable cell types generated from varying donors may secrete EVs with different functional properties (112).”